Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study

類似資料

• Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
  著者:: Karachaliou, Niki, 等
  出版事項: (2014)
• Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study
  著者:: Liao, Bin-Chi, 等
  出版事項: (2012)
• Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
  著者:: Karachaliou, Niki, 等
  出版事項: (2014)
• Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river’s DELTA?
  著者:: Morales-Espinosa, Daniela, 等
  出版事項: (2015)
• Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC
  著者:: Rosell, Rafael, 等
  出版事項: (2018)